抗VEGF药物在湿性年龄相关性黄斑变性中的应用进展

Current advance in the application of anti-vascular endothelial growth factor drugs in wet age-related macular degeneration

摘要:

年龄相关性黄斑变性(ARMD)是导致老年人不可逆失明的主要原因之一，ARMD致失明患者中，以脉络膜新生血管(CNV)为特征的湿性ARMD比例达到90%。随着我国老年人口比例的不断上升，湿性ARMD已经成为一个日益严重的社会医学问题。目前，针对湿性ARMD的治疗方案主要是抗血管内皮生长因子(VEGF)药物的应用，这类药物抑制了CNV的发展，提高了患者视力，改善了预后，降低了致盲率。但是在治疗过程中的无反应、长期用药后的维持和用药后的耐受、不良反应以及用药的经济效益也是我们需要关注的。本文就近年来临床用于治疗湿性ARMD的药物进行综述。

Abstract:

Age-related macular degeneration(ARMD)is one of the main causes which lead to irreversible blindness. Wet ARMD, which is featured by choroidal neovascularization(CNV), takes up 90% in ARMD related blind patients. With the increasing population of aged people in China, wet ARMD has become a severe social and medical issues. Currently, management aiming at wet ARMD is the applications of anti-VEGF agents. Anti-VEGF drugs not only postpone the development of CNV, but also preserve the visual function, improve the prognosis, and reduce the incidence of blindness. However, we still need to focus on the non-response during treatment, long-term maintenance, drug resistance, adverse reactions, and economic effectiveness. Here we review the recent clinical medications on wet ARMD.